Endocrine Society Store

Now, you can watch and learn about the latest recommendations from professionals in the field at your own pace. With Meet the Professor sessions and nine hours of live programming spanning different specialized areas, there is something valuable for every endocrinology specialty. Watch over nine hours of live programming to learn the latest innovations from our premier clinical program.

These recordings include 35 presentations featuring clinical cases, live question-and-answer sessions with experts under these categories:

• Adrenal
• Adrenal/Pituitary
• Calcium & Bone
• Diabetes
• Female Reproduction
• Lipid & Obesity
• Male Reproduction
• Pituitary
• Thyroid
• Transgender Care

Earn continuing education credits! CEU 2023 recordings are certified for 26.25 AMA PRA Category 1 Credits™ and AAPA Category 1 CME Credits and Nursing Contact Hours (including 7.5 pharmacotherapeutic contact hours).

Available sessions include:

• Overview and Update on Rare Bone Disorders
• Hypertriglyceridemic Pancreatitis
• Male Hormonal Contraceptive Trials: Applicability to Clinical Practice
• Initiation and Management of Hormone Therapy in Transgender and Gender Diverse Individuals: Role of the General Endocrinologist
• Update on Menopause Hormone Therapy
• The Spectrum of Primary Aldosteronism
• Adrenal Insufficiency in Opioid Use (and Other Causes of Adrenal Insufficiencies, Case Reports)- When to Suspect and How to Treat
• Management of Hyperglycemia in Type 2 Diabetes
• Diabetic Retinopathy: Prevention and Treatment
• Challenging Cases of Abnormal TFTs
• Challenging Cases in Thyroid Cancer and Indications for Local and Systemic Therapy
• COVID and the Pituitary
• Sodium Disorders and the Role of Copeptin
• Fracture Risk and the Management of Denosumab Discontinuation
• A Year in Obesity Medicine
• Update on Various Modalities of Testosterone Replacement
• Update on Female Contraception: What Does the Endocrinologist Need to Know?
• Hypercalcemia of Malignancy – Etiology and Approach to Management
• Optimization of Skeletal Health in the Perioperative Setting
• Automated Insulin Delivery Systems: Current Devices and the Future of Closing the Loop
• Inpatient Diabetes Management Updates
• CKD Prevention and Prevention of Progression
• Using Diabetes Technology in Patients with Type 2 Diabetes
• Diagnosis and Management of Mild ACTH-Independent Cortisol Excess
• Pearls in Imaging of the Pituitary and Adrenal Glands for the Endocrinologist
• Large Adrenal Masses- Remove or Follow?
• New Therapeutics for Delaying Type 1 Diabetes
• Pituitary Implications for Childhood Cancer Survivors
• Management of Thyroid Eye Disease
• Pituitary Dysfunction and Quality of Life
• Thyroid Nodule Management
• Challenging Pituitary Cases, When to Consider Radiation or Other Therapies
• Medullary Thyroid Carcinoma
• Update in Thyroid Cytology and Pathology
• ATA Risk Stratification, Response to Therapy, and Long-Term Follow Up

On-the-go learning features include:

• Synchronized presentation slides with recorded audio presentations
• Searchable presentations by session title, presentation title, and presenter name
• Downloadable MP3 audio files for a presentation
• Available for the iPhone, iPad, and Android

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 26.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

AAPA Category 1 CME Credits
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 26.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 10/21/2023 to 12/31/2025. AAPA reference number: CME-209953.

This nursing continuing professional development activity was approved by the Virginia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. This on-demand activity is worth 26.25 contact hours (including 7.5 pharmacotherapeutic contact hours) . Criteria for successful completion includes credit awarded commensurate with participation and submission of an evaluation. Nursing contact hours will be awarded for completion of this activity until September 20, 2025.

AMA PRA Category 1 Credits™, and AAPA Category 1 CME Credits for the activities related to this material must be claimed by December 31, 2025. 

Faculty and Disclosures 

STATEMENT OF INDEPENDENCE 

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Clinical Endocrinology Update Steering Committee. 

DISCLOSURE POLICY 

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable. 

The following CEU Committee Members reported relevant financial relationships:

• Jennifer Sipos, MD: Author, Up-To-Date
• Anders L. Carlson, MD: Research Investigator, Insulet, Medtronic, Abbott, Dexcom, Sanofi, Novo Nordisk, Eli Lilly, UnitedHealth; Consulting/Advisory Board, Medtronic
• Whitney Woodmansee, MD: Previous Employer, Eli Lilly and Company; Consulting, Biomedical Systems; Advisory Board, Corcept; Stock Option: Eli Lilly and Company

The following CEU steering committee members reported no financial relationships:

• Sara Ahmadi, MD; Leonor Corsino, MD, MHS; Shaishav Dhage, MBBS, DNB(Medicine), MRCP, MD; William Troy Donahoo, MD; Matthew T. Drake, MD, PhD; Anne Knape MSN, APRN-NP;  Adina Turcu, MD, MS
• Disclosure information for presenters is included in their individual recorded presentations.
• Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The relevant financial relationships listed for these individuals has been mitigated and there are no other relevant financial relationships with ineligible companies for those with the ability to control the content for this activity.